DGX vs NEO
DGX: A leading national provider of diagnostic testing and medical insights, delivering clinical laboratory services through an extensive network of patient centers and hospitals. NEO: NeoGenomics is a leading provider of oncology diagnostic solutions that empower clinicians and patients with actionable insights to guide personalized cancer care.
Side-by-side fundamentals
| Metric | DGX | NEO | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $230.81 | $16.02 | |
| Market cap | $25.5B | $2.1B | |
| P/E as of 2026-10-08 | 24.44 | n/a | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | 7.73 | n/a | |
| Net margin FY2025, SEC XBRL | +9.0% | n/a | |
| Operating margin FY2025, SEC XBRL | +14.1% | n/a | |
| ROE FY2025, SEC XBRL | +13.8% | -12.9% | DGX higher |
| ROA FY2025, SEC XBRL | +6.1% | -7.9% | DGX higher |
| Debt / equity as of 2026-09-03 | 0.75 | 0.48 | NEO lower |
| Revenue growth (YoY) as of 2026-09-03 | +9.9% | +11.2% | NEO higher |
| Revenue CAGR (3y) SEC XBRL | +3.7% | n/a | |
| Dividend yield as of 2026-09-03 | +1.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | 11 | n/a | |
| Beta as of 2026-09-03 | 0.15 | 1.18 | |
| 1-year return as of 2026-10-08 close | +27.6% | +74.7% | NEO higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.